S18 / Operate

End-to-end trial management.

Full sponsor-side trial leadership for small biotechs without internal team. Multi-year engagement model.

5 min read

You'll leave with: What full sponsor-side trial leadership looks like when the sponsor doesn't have an internal team.

Note: Year-1 partial — Year-2 yes after first anchor engagement.

/ Who this is for

The fit.

Small biotechs without internal trial team. Combination-product founders pre-MAA.

/ The work itself

What this delivers.

Quality-first end-to-end trial leadership. RBQM, CtQ, governance baked in. Runway-conscious orientation.

/ Why this matters

Where the edge is.

Quality-first end-to-end (RBQM + CtQ + governance baked in). Runway-conscious orientation — trial design that respects capital reality.

/ How engagement runs

The shape of the work.

Every engagement is scoped per situation. The shape — focused diagnostic, structured implementation, ongoing partnership — emerges from the discovery conversation rather than a fixed package. Some engagements are short and intense; some are months-long structural builds; some are recurring quality oversight. We talk first, then scope.

Discovery.

Confirm trial vision and runway constraints.

Scoping.

Multi-year engagement model.

Lead.

End-to-end trial leadership.

Outcomes.

MAA-ready package, post-trial obligations.

What to do next.

If this is the work in front of you, the next step is a conversation. I read every message and respond personally. No contact forms. No sales sequence. Just a discovery conversation to understand whether the fit is real, and what the shape of the work would be.

Cadence promise: I publish weekly on regulated AI governance. If a week is missed, the journal entry explaining why goes up in real-time.

DM on LinkedIn → Email → Browse all collaboration shapes →